Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. US Food & Drug Administration website.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. Licensed wholesalers will be able to import larger quantities of cannabis-based products, and hold supplies for future use by patients with prescriptions, according to a government release.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

JANUARY 26, 2022

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. Our promising Phase 3 results lead us to apply for the Innovation Passport. Berra Yazar-Klosinski, Ph.D. Corine de Boer, M.D.,

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 98

CBD THC Conditions Medicine 98

Healer

JUNE 28, 2019

Beyond decreasing the intensity of pain, many patients report that cannabis changes the nature of the pain, making it more bearable and less distracting. Many patients report positive mood, relaxation, laughter, social comfort, time distortion, and the intensification of ordinary experiences (e.g. Abstract: Medical Study .

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

MMJ Recs

JUNE 25, 2021

The medical relief provided by these new laws helped many patients who had been suffering from long-term conditions. According to the Pennsylvania Department of Health, over half a million people in the state have a medical marijuana card for various health conditions such as cancer and epilepsy.

Conditions 52

Conditions Law Marijuana Events 52

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Doctors and patients had to register on the Compassionate Use Registry , an online database maintained by the Florida Department of Health.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Refractory paediatric epilepsy. The review, however, did not cover patient access to medicinal cannabis.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. FDA considers delta-8 THC to pose serious health and safety risks. FDA Warning Letters. meat, milk, and eggs).

THC 52

THC CBD Food Pets 52

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. “Our fourth quarter and full year results for 2019 reflect an exceptional launch year for Epidiolex.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

MARCH 6, 2020

KLS-13019 has not been reviewed or approved for patient use by the U.S. It’s safety and efficacy have not been confirmed by FDA-approved research. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax anticipates enrollment of the first patient by early second quarter of 2022. to conduct this study in Canada. For more information, please visit www.virpaxpharma.com.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

JULY 15, 2022

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS About Sesen Bio.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Canna Law Blog

NOVEMBER 16, 2021

In the event a Tribe or State doesn’t develop a plan or the plan is rejected by USDA, then growers will just follow the overall system put together by USDA (these directives are very similar to the standards set out in the 2018 Farm Bill, legalizing hemp). .

DEA 88

DEA Business Banking Food 88

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Life Network

AUGUST 15, 2019

Videos Videos See all Jay and Silent Bob Reboot July 20, 2019 Canada Day: J-Geezy’s latest Studio 710-filmed visual drops July 1, 2019 Cooking with Cannabis Video June 23, 2019 News & Events. A patient’s story: A conversation with Chad Jackett of Cannabis Growers of Canada and Liberty Farms. Flix Anonymous. Interviews.

Strains 80

Strains CBD Terpenes Cannabinoids 80

Cannabis Law Report

FEBRUARY 18, 2020

The researchers found overwhelming benefits for the economy, public health and safety, and thusly recommended the development of a comprehensive regulatory framework for marijuana use in the city. . A medical card issued by the state provides patients with the right to purchase and consume marijuana. patient application.

Marijuana 59

Marijuana Consumption Dispensary Vaping 59

The Cannigma

DECEMBER 22, 2021

It doesn’t mean, necessarily, that the market should go to full legalization within a year or two, because it won’t happen so fast, but you can have more patients with other medical indications that were not given cannabis before. Obviously, that means that there are more patients and there are more products to sell.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

OCTOBER 26, 2019

Sponsors must also ensure compliance with the relevant guidelines as to good clinical practice and safety monitoring and reporting, and ensure that the use of personal information complies with the Privacy Act 1988.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. alcoholic beverages, caffeine, and tobacco).

Law 40

Law Seed-To-Sale Hemp Recreational 40